Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SCPH |
---|---|---|
09:32 ET | 251 | 4.02 |
09:35 ET | 200 | 4.05 |
09:42 ET | 200 | 4.04 |
09:44 ET | 100 | 4.07 |
09:46 ET | 200 | 4.07 |
09:48 ET | 300 | 4.04 |
09:55 ET | 300 | 4.04 |
10:04 ET | 2280 | 4.05 |
10:06 ET | 100 | 4.05 |
10:08 ET | 100 | 4.04 |
10:11 ET | 1000 | 4.0517 |
10:15 ET | 100 | 4.045 |
10:20 ET | 100 | 4.04 |
10:26 ET | 1357 | 4.03 |
10:27 ET | 1788 | 4.0299 |
10:29 ET | 952 | 4.02 |
10:31 ET | 782 | 4.02 |
10:33 ET | 340 | 4.026 |
10:36 ET | 200 | 4.02 |
10:38 ET | 100 | 4.02 |
10:42 ET | 200 | 4.03 |
10:44 ET | 100 | 4.03 |
11:00 ET | 100 | 4.05 |
11:02 ET | 400 | 4.06 |
11:05 ET | 1800 | 4.08 |
11:07 ET | 2100 | 4.07 |
11:12 ET | 100 | 4.08 |
11:14 ET | 200 | 4.075 |
11:16 ET | 1157 | 4.075 |
11:18 ET | 948 | 4.0684 |
11:21 ET | 100 | 4.06 |
11:25 ET | 100 | 4.065 |
11:30 ET | 400 | 4.05 |
11:50 ET | 100 | 4.06 |
12:06 ET | 100 | 4.06 |
12:14 ET | 200 | 4.06 |
12:15 ET | 100 | 4.06 |
12:26 ET | 203 | 4.07 |
12:28 ET | 100 | 4.07 |
12:30 ET | 819 | 4.07 |
12:39 ET | 100 | 4.08 |
12:42 ET | 235 | 4.07 |
12:44 ET | 100 | 4.07 |
12:46 ET | 100 | 4.08 |
12:50 ET | 100 | 4.07 |
12:53 ET | 100 | 4.08 |
01:02 ET | 100 | 4.07 |
01:06 ET | 1065 | 4.05 |
01:08 ET | 100 | 4.055 |
01:09 ET | 200 | 4.07 |
01:13 ET | 100 | 4.07 |
01:24 ET | 1000 | 4.05 |
01:26 ET | 1400 | 4.03 |
01:31 ET | 300 | 4.03 |
01:33 ET | 325 | 4.035 |
01:42 ET | 400 | 4.04 |
01:44 ET | 1010 | 4.04 |
01:45 ET | 300 | 4.03 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
scPharmaceuticals Inc | 201.6M | -2.6x | --- |
Precigen Inc | 232.1M | -1.5x | --- |
Global Pharmatech Inc | 138.3M | -3.6x | --- |
Hongchang International Co Ltd | 121.0M | -388.8x | --- |
Telomir Pharmaceuticals Inc | 125.5M | -6.1x | --- |
Biostem Technologies Inc | 340.9M | 68.0x | --- |
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $201.6M |
---|---|
Revenue (TTM) | $24.0M |
Shares Outstanding | 50.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.17 |
EPS | $-1.56 |
Book Value | $1.03 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | 8.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -251.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.